(Q42673894)

4 November 2017

title

Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease (English)

1 reference

4 November 2017

1 reference

chronic liver disease

0 references

1 reference

1 reference

Keeffe EB

1

1 reference

4 November 2017

Iwarson S

2

1 reference

4 November 2017

McMahon BJ

3

1 reference

4 November 2017

Lindsay KL

4

1 reference

4 November 2017

Koff RS

5

1 reference

4 November 2017

Manns M

6

1 reference

4 November 2017

Baumgarten R

7

1 reference

4 November 2017

Wiese M

8

1 reference

4 November 2017

Fourneau M

9

1 reference

4 November 2017

Safary A

10

1 reference

4 November 2017

Clemens R

11

1 reference

4 November 2017

Krause DS

12

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 March 1998

1 reference

4 November 2017

1 reference

4 November 2017

volume

27

1 reference

4 November 2017

issue

3

1 reference

4 November 2017

page(s)

881-886

1 reference

Relapsing hepatitis A. Review of 14 cases and literature survey

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Atypical clinical manifestations of hepatitis A

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Acute type A hepatitis in three patients with chronic HBV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

The clinical course of acute type A hepatitis in chronic HBsAg carriers--a report of 3 cases

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Hepatitis A infection in chronic carriers of hepatitis B virus.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Placebo-controlled efficacy study of hepatitis A vaccine in Valdivia, Chile

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Interruption of an outbreak of hepatitis A in two villages by vaccination

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Long-term immunogenicity and safety of an inactivated hepatitis A vaccine in haemophilic patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Safety and immunogenicity of hepatitis A vaccine in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Vaccination against hepatitis A virus in French hemophilic children

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Analysis of immunoassays to detect antibodies to hepatitis A virus (anti-HAV) and anti-HAV immunoglobulin M.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Hepatitis B vaccination: protection for how long and against what?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Clinical trial with inactivated hepatitis A vaccine and recommendations for its use

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510270336

7 January 2021

Identifiers

DOI

10.1002/HEP.510270336

1 reference

4 November 2017

1 reference